Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer

NCT06547736 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: SHR-A2102 or/and HRS-4642
DRUG: SHR-A1904 or/and HRS-4642
DRUG: SHR-A1811 or/and HRS-4642
DRUG: SHR-A2102, HRS4642 and Adebrelimab

Sponsor

Fudan University

Collaborators

Jiangsu HengRui Medicine Co., Ltd.